Literature DB >> 22155907

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.

Alessandra Viganò1, Stefano Mora, Vania Giacomet, Sara Stucchi, Valeria Manfredini, Clara Gabiano, Filippo Salvini, Monica Cellini, Enrica Tamburrini, Maria Puzzovio, Gian Vincenzo Zuccotti.   

Abstract

BACKGROUND: Growth impairment and bone toxicity due to tenofovir disoproxil fumarate (TDF) fetal exposure has been described mainly in animals. We evaluated growth pattern and bone health in TDF-exposed HIV-uninfected children born to HIV-infected mothers, defined as seroreverters (SR).
METHODS: This was a multicentre observational cross-sectional cohort study enrolling 68 SR who were in utero exposed to an antiretroviral regimen including (TDF+) or not including (TDF-) tenofovir. Neonatal data and duration of antiretroviral exposure were recorded. At enrolment, anthropometric measures, tibial speed of sound (SOS) by quantitative ultrasound and several parameters of bone metabolism were assessed.
RESULTS: Gestational age and median in utero antiretroviral exposure were similar in subjects exposed to TDF (n=33) and those non-exposed (n =35). Age at enrolment was comparable in the two groups (TDF-exposed range 11.8-76.2 months and TDF non-exposed range 11.8-77.9 months). The incidence of low weight and length measurements (<10th percentiles) at birth was similar in TDF-exposed and TDF non-exposed. Normal growth development was found in both groups of subjects at enrolment. The median (0.6; range -2.4-2.6) SOS z-score of TDF-exposed was similar to the median (0.8; range -2.2-4.4) SOS z-score of TDF non-exposed (Student's t=0.84; P=0.40). Parameters of bone metabolism were similar in the two groups.
CONCLUSIONS: Exposure to TDF during pregnancy does not impair growth patterns, bone health and markers of bone metabolism in SR infants and young children born to HIV-infected women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155907     DOI: 10.3851/IMP1909

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  24 in total

Review 1.  Management of hepatitis B in special populations.

Authors:  Kali Zhou; Norah Terrault
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-06-08       Impact factor: 3.043

2.  "I Did Not Want to Give Birth to a Child Who has HIV": Experiences Using PrEP During Pregnancy Among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples.

Authors:  Jillian Pintye; Kristin M Beima-Sofie; Grace Kimemia; Kenneth Ngure; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Josephine Odoyo; Nelly Mugo; Elizabeth A Bukusi; Maureen C Kelley; Grace C John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2017-11-01       Impact factor: 3.731

3.  Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

Authors:  George K Siberry; Denise L Jacobson; Heidi J Kalkwarf; Julia W Wu; Linda A DiMeglio; Ram Yogev; Katherine M Knapp; Justin J Wheeler; Laurie Butler; Rohan Hazra; Tracie L Miller; George R Seage; Russell B Van Dyke; Emily Barr; Mariam Davtyan; Lynne M Mofenson; Kenneth C Rich
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

Review 4.  HIV and Bone Complications: Understudied Populations and New Management Strategies.

Authors:  Michael T Yin; Todd T Brown
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

5.  Tenofovir rescue therapy in pregnant females with chronic hepatitis B.

Authors:  Yu-Hong Hu; Min Liu; Wei Yi; Yan-Jun Cao; Hao-Dong Cai
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.

Authors:  Luiz Eduardo Osorio; Maria Ines Boechat; Mark Mirochnick; Newton Kumwenda; Regis Kreitchmann; Lynda Emel; Jorge Pinto; Esau Joao; Breno Santos; Molly Swenson; Kathleen George; Paul Sato; Lynne Mofenson; Karin Nielsen-Saines
Journal:  Pediatr Infect Dis J       Date:  2017-02       Impact factor: 2.129

7.  Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation.

Authors:  Denise L Jacobson; Kunjal Patel; Paige L Williams; Mitchell E Geffner; George K Siberry; Linda A DiMeglio; Marilyn J Crain; Ayesha Mirza; Janet S Chen; Elizabeth McFarland; Deborah Kacanek; Margarita Silio; Kenneth Rich; William Borkowsky; Russell B Van Dyke; Tracie L Miller
Journal:  Pediatr Infect Dis J       Date:  2017-02       Impact factor: 2.129

8.  Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.

Authors:  Sarah K Himes; Julia W Wu; Denise L Jacobson; Katherine Tassiopoulos; Rohan Hazra; Deborah Kacanek; Russell B Van Dyke; Kenneth C Rich; George K Siberry; Marilyn A Huestis
Journal:  Pediatr Infect Dis J       Date:  2015-08       Impact factor: 2.129

Review 9.  Bone health in HIV-infected children and adolescents.

Authors:  Allison R Eckard; Stefano Mora
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

10.  HIV-exposed infants: rethinking care for a lifelong condition.

Authors:  Nandita Sugandhi; Jessica Rodrigues; Maria Kim; Saeed Ahmed; Anouk Amzel; Mike Tolle; Eric J Dziuban; Scott E Kellerman; Emilia Rivadeneira
Journal:  AIDS       Date:  2013-11       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.